[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"congestive-heart-failure-chronic\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:congestive-heart-failure-chronic":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,48,73,113,140,169,193],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":30,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100585575","health-coaching-for-patients-with-cardiovascular-disease-100585575",false,"NCT06904144","Health Coaching for Patients With Cardiovascular Disease","Health Coaching for Patients With Cardiovascular Disease: A Mixed-Methods Evaluation of the Impact on Patient Outcomes and Provider Satisfaction and Acceptability","Inclusion Criteria:\n\n* 18 years of age or older\n* diagnosis of coronary artery disease resulting in myocardial infarction and\u002For congestive heart failure\n* physical condition effectively managed by routine healthcare and not requiring urgent medical attention\n* ability to communicate in English\n* access to a working phone or computer and ability to communicate via phone or computer.\n\nExclusion Criteria:\n\n* Patients who have had chest coronary artery bypass surgery\n* Documented cognitive and\u002For major psychiatric disorders, including dementia, Alzheimer's, depression or anxiety uncontrolled by anxiolytic, anti-psychotic, and\u002For anti-depressants and\u002For PHQ-9 score 15-27 and GAD-7 score \\>15\n* current alcohol or drug dependency\n* resident of extended care\u002Fskilled facility\n* prisoners or ward of state.","ALL","18 Years",{"count":19,"type":20},70,"ESTIMATED","INTERVENTIONAL",[23],"NA","For patients discharged with a diagnosis of cardiovascular disease coronary artery disease resulting in myocardial infarction and\u002For congestive heart failure, this study will evaluate if the addition of 12 virtual health coaching sessions over the course of 16 weeks will improve physiological, psychological, and social health outcomes, prove acceptable and satisfactory for these patients with CVD, decrease CVD-related questions and concerns sent to the provider via MyChart, and reduce hospital readmission rates over a 90-day period as compared to patients discharged with the same diagnosis who receive standard post-discharge care. The study will also evaluate the perceptions of physician and advanced practice providers related to the health coach as part of the interprofessional team and the amount of time spent addressing CVD-related patient questions and concerns via MyChart messages.",[26,27,28,29],"Congestive Heart Failure Treated","Myocardial Infarction (MI)","Coronary Artery Disease","Congestive Heart Failure Chronic",[31,32,33,34],"health coaching","coronary artery disease","congestive heart failure","myocardial infarction","NOT_YET_RECRUITING","2026-06-30",{"date":38,"type":39},"2026-07-01","ACTUAL",{"date":41,"type":20},"2026-10-01",{"date":43,"type":20},"2028-10-01",{"name":45,"class":46},"Ohio State University","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":58,"conditions":59,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":47},"100620378","palliative-care-for-people-with-hf-100620378","NCT07356843","Palliative Care for People With HF","Implementing Community Palliative Care for People With Heart Failure","Inclusion Criteria:\n\n* Outpatient clinician or staff member (e.g. physician, physician assistant, nurse practitioner, registered nurse, social worker, psychologist, medical assistant) or healthcare leadership personnel (e.g. Chief Nursing Officer, Clinic Medical Director etc.)\n* at least 6 months of experience caring for patients with HF\n* 18 years or older\n\nExclusion Criteria:\n\n\\-",{"count":56,"type":20},20,"OBSERVATIONAL","Imagine having heart failure, a condition where the heart struggles to pump blood, making daily life hard. People with heart failure often don't feel well and end up going to the hospital a lot. Many of these people could feel better with extra help, but there aren't many programs that offer support beyond usual heart failure treatments. That's where the ADAPT program comes in, which stands for \"Advancing Symptom Alleviation with Palliative Treatment.\" In this program, nurses and social workers call people weekly, helping them manage their toughest symptoms, offering tools to cope with heart failure, and keeping the patients' current doctors involved. We tested this program in a research study with heart failure patients and found that it improved their quality of life and lowered depression, anxiety, and heart failure symptoms. The question now is if the ADAPT program will work in the community, outside of a research setting, so that more people could benefit from it. Specifically, can the ADAPT program work well in new places? Will patients and their families find it helpful? Most importantly, can it help improve the lives of people with heart failure in these new settings? To answer these questions, the study team will work with healthcare providers to 1) ask how to adjust the ADAPT program to work well in various settings (e.g. primary care, heart failure clinic) and 2) use this information to create simple materials and trainings to help them easily provide ADAPT. This will prepare for the next phase of this project to test out the new ADAPT program.",[60,61,62,29],"Congestive Heart Failure","Congestive Heart Failure(CHF)","Congestive Heart Failure (CHF)","RECRUITING","2026-06-15",{"date":66,"type":39},"2026-06-16",{"date":68,"type":39},"2025-10-29",{"date":70,"type":20},"2028-09",{"name":72,"class":46},"Indiana University",{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":16,"minAge":81,"maxAge":4,"enrollmentInfo":82,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":84,"conditions":85,"keywords":90,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":47},"100586000","ai-based-monitoring-system-for-chronic-heart-failure-with-advanced-wearable-and-mini-invasive-devices-100586000","NCT06909682","AI-Based Monitoring System for Chronic Heart Failure With Advanced Wearable and Mini-Invasive Devices","Smart Monitoring and Analysis System Based on Artificial Intelligence for Patients With Chronic Heart Failure Using Advanced Mini-Invasive and Wearable Medical Devices","SMART-CARE","Inclusion Criteria\n\n* Age ≥ 18 years (adults of any sex)\n* Confirmed diagnosis of chronic heart failure (CHF) for at least 6 months prior to screening\n* Stable on optimized heart failure therapy for at least one month before enrollment\n* Any left ventricular ejection fraction (LVEF) classification, including:\n\n  * Heart Failure with Reduced Ejection Fraction (HFrEF)\n  * Heart Failure with Mid-Range Ejection Fraction (HFmrEF)\n  * Heart Failure with Preserved Ejection Fraction (HFpEF)\n* NYHA Functional Class I, II, or III\n* History of at least one hospital admission or outpatient visit in the past 12 months requiring intravenous (IV) diuretics, vasodilators, or inotropes for CHF exacerbation\n* Ability to provide written informed consent or availability of a legally authorized representative Exclusion Criteria\n* NYHA Functional Class IV or anticipated heart transplant or ventricular assist device (VAD) implantation within 6 months of screening\n* Severe renal impairment (eGFR \\\u003C 30 mL\u002Fmin\u002F1.73 m²) or dialysis dependence\n* Terminal comorbidities (e.g., advanced cancer, end-stage pulmonary disease) significantly limiting life expectancy\n* Pregnancy\n* Presence of skin conditions or allergies preventing prolonged use of a wearable device\n* Inability to comply with study procedures (e.g., cognitive impairment, significant psychiatric disorders)","19 Years",{"count":83,"type":20},205,"The goal of this observational, multicenter study is to evaluate whether AI-driven remote monitoring using a mini-invasive wearable device can improve clinical outcomes in adult patients (≥18 years) with chronic heart failure (CHF).\n\nThe main questions it aims to answer are:\n\n* Can continuous remote monitoring reduce hospital admissions (emergency visits and hospitalizations) by 20% compared to standard care?\n* Does wearable-based remote monitoring improve functional, biochemical, and instrumental parameters in CHF patients? Researchers will compare patients using the wearable device (intervention group) to those receiving standard clinical follow-up (control group) to assess whether AI-driven monitoring leads to fewer hospitalizations, better disease management, and improved quality of life.\n\nParticipants will:\n\n* Wear the EmbracePlus (Empatica Inc.) device continuously for six months (intervention group only).\n* Have their biometric data (SpO₂, HRV, EDA, respiratory rate, temperature, sleep quality) monitored remotely.\n* Receive automated alerts and teleconsultations if abnormal physiological changes are detected.\n* Attend scheduled follow-up visits (remote and in-person) for clinical evaluation and treatment adjustments.\n\nThe study aims to provide real-world evidence on whether integrating wearable health technology with AI analytics can enhance CHF management and improve patient outcomes.",[86,87,88,89,29],"Chronic Heart Failure","Cardiovascular Diseases","Heart Failure With Reduced Ejection Fraction (HFrEF)","Heart Failure With Preserved Ejection Fraction (HFPEF)",[91,92,93,94,95,96,97,98,99,100,101,102,103],"Wearable Medical Devices","Remote Patient Monitoring","Artificial Intelligence in Cardiology","Smart Wearables for Healthcare","Observational Study in Heart Failure","AI-Based Predictive Modeling","Telemedicine in Heart Failure","Non-Invasive Health Monitoring","Personalized Medicine for CHF","Quality of Life Improvement in Heart Failure","Heart Failure Readmission Prevention","Telehealth in Chronic Disease Management","Digital Health Solutions for Heart Disease","2026-03-09",{"date":106,"type":39},"2026-03-11",{"date":108,"type":39},"2025-08-01",{"date":110,"type":20},"2027-02-02",{"name":112,"class":46},"University of Salerno",{"id":114,"slug":115,"hasResults":11,"nctId":116,"briefTitle":117,"officialTitle":118,"acronym":119,"eligibilityCriteria":120,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":121,"targetDuration":4,"studyType":21,"phases":123,"briefSummary":124,"conditions":125,"keywords":127,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":130,"startDateStruct":132,"completionDateStruct":134,"leadSponsor":136,"locationsCount":139},"100624668","evaluation-of-the-heartlogic-diagnostic-in-optimizing-guideline-directed-medical-therapy-in-patients-with-congestive-heart-failure-and-chronically-low-ejection-fractions-efs-100624668","NCT07412626","Evaluation of the HeartLogic Diagnostic in Optimizing Guideline-directed Medical Therapy in Patients With Congestive Heart Failure and Chronically Low Ejection Fractions (EFs)","HeartLogic Optimization of CHF Medications in Chronic Low EF Population: A Follow-on Study","Heartlogic ISR","Inclusion Criteria:\n\n* Age 18 years or older\n* EF \\\u003C\u002F=35%\n* Prior hospitalization within the last two years or prior decompensation to NYHA class III or IV over the last 12 months that was treated without hospitalization\n* HeartLogic capable ICD or CRT-D (Patients with HeartLogic capable ICD or CRT-D can be enrolled at time of de novo implantation or generator change out or at the time of the 2 week wound check. Prior Heart logic capable ICF or CRT-D implants can be enrolled if heart failure hospitalization shows decompensation within six months (prior implants must have at least 1 year battery life)\n\nExclusion Criteria:\n\n* Refuse to give consent\n* Have Life expectancy of less than one-year\n* Documented noncompliance that limits medication use\n* Patients on Dialysis (renal insufficiency but not on dialysis is NOT an exclusion)\n* Pregnancy",{"count":122,"type":20},135,[23],"The goal of this trial is to determine if the addition of the Heart Logic diagnostic alerts to standard of care therapies will lessen hospitalizations and improve quality of life in patients with heart failure.",[29,126],"Low Ejection Fraction",[128],"Heart Failure","2026-02-13",{"date":131,"type":39},"2026-02-17",{"date":133,"type":20},"2026-04-01",{"date":135,"type":20},"2028-03",{"name":137,"class":138},"Robert Pickett","INDUSTRY",2,{"id":141,"slug":142,"hasResults":11,"nctId":143,"briefTitle":144,"officialTitle":145,"acronym":146,"eligibilityCriteria":147,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":148,"enrollmentInfo":149,"targetDuration":151,"studyType":57,"phases":4,"briefSummary":152,"conditions":153,"keywords":156,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":161,"lastUpdatePostDateStruct":162,"startDateStruct":164,"completionDateStruct":165,"leadSponsor":167,"locationsCount":47},"100614811","depressive-symptoms-cognitive-impairment-and-outcomes-in-hospitalized-chronic-heart-failure-patients-100614811","NCT07284446","Depressive Symptoms, Cognitive Impairment, and Outcomes in Hospitalized Chronic Heart Failure Patients","Prevalence of Depressive Symptoms and Cognitive Impairment and Their Association With Worse Outcomes in a Cohort of Hospitalized Patients With Chronic Heart Failure","DSCI-CHF","Inclusion Criteria:\n\n* patient hospitalized primarily for CHF exacerbation;\n* clinically stable, able to provide informed consent;\n* do not have severe cognitive impairment that would preclude valid questionnaire administration.\n\nExclusion Criteria:\n\n* hospitalization for acute heart failure;\n* total length of hospital stay \\\u003C96 hours;\n* absence of transthoracic echocardiography (TTE) within the last 12 months and no TTE planned;\n* severe visual impairment preventing completion of the visual part of the Montreal Cognitive Assessment;\n* refusal to participate.","85 Years",{"count":150,"type":20},300,"12 Months","The goal of this observational study is to learn about the prevalence of depressive symptoms and cognitive impairment and their association with worse outcomes in a cohort of hospitalized patients between the ages of 18 ang 85 years with chronic heart failure. The main question it aims to answer is:\n\n• Does the presence of depressive symptoms and cognitive impairment lead to worse outcomes in a cohort of hospitalized patients with chronic heart failure? Participants who are hospitalized due to exacerbation of chronic heart failure will answer survey questions to assess their cognitive function and depressive symptoms.",[29,154,155],"Cognitive Impairment, Mild","Depressive Symptoms Mild to Moderate in Severity",[60,157,158,159,160],"Mild Cognitive Impairment","Long-term Outcomes","Mild Depressive Symptoms","Rehospitalizations","2025-12-02",{"date":163,"type":39},"2025-12-16",{"date":161,"type":39},{"date":166,"type":20},"2028-12-02",{"name":168,"class":46},"Lithuanian University of Health Sciences",{"id":170,"slug":171,"hasResults":11,"nctId":172,"briefTitle":173,"officialTitle":174,"acronym":4,"eligibilityCriteria":175,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":176,"targetDuration":4,"studyType":21,"phases":178,"briefSummary":179,"conditions":180,"keywords":181,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":184,"lastUpdatePostDateStruct":185,"startDateStruct":187,"completionDateStruct":189,"leadSponsor":191,"locationsCount":47},"100600730","eat-well-heart-failure-100600730","NCT07101289","Eat Well Heart Failure","Eat Well Produce Prescription for Duke Health Patients With Congestive Heart Failure","Inclusion Criteria:\n\n* Age 18 or older\n* Diagnosis of CHF regardless of ejection fraction AND\n* Hospitalization or ED visit within the past 12 months AND\n* At risk of food insecurity as defined by one of the following:\n\nscreened positive for financial instability (medium risk and up) or food insecurity in the past 12 months minimum OR a Medicaid or dual eligible enrollee\n\n* English as preferred language\n* Valid email address (for virtual health coaching intervention)\n* NC mailing address\n\nExclusion Criteria:\n\n* History of dialysis or end stage renal disease OR\n* History of LVAD or heart transplant.",{"count":177,"type":20},900,[23],"The purpose of this parallel pragmatic randomized controlled trial (RCT) is to evaluate the impact of Eat Well (an evidence-based 'Food is Medicine' produce prescription program) with varying levels of behavioral support on health outcomes and care utilization patterns of Duke Health patients diagnosed with congestive heart failure (CHF). Objectives of this three arm trial include testing the effectiveness of Eat Well alone with minimal behavioral support and Eat Well with intensified behavioral support based on an evidence based approach to improve CHF patients' health outcomes, estimating health care cost savings between the intervention and control arms, and identifying barriers, facilitators, and potential strategies to enhance Eat Well effectiveness and implementation.",[29],[182,183],"prescription produce","behavioral support","2025-11-07",{"date":186,"type":39},"2025-11-12",{"date":188,"type":39},"2025-10-22",{"date":190,"type":20},"2027-12",{"name":192,"class":46},"Duke University",{"id":194,"slug":195,"hasResults":11,"nctId":196,"briefTitle":197,"officialTitle":198,"acronym":199,"eligibilityCriteria":200,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":201,"enrollmentInfo":202,"targetDuration":4,"studyType":21,"phases":204,"briefSummary":205,"conditions":206,"keywords":210,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":214,"lastUpdatePostDateStruct":215,"startDateStruct":217,"completionDateStruct":219,"leadSponsor":220,"locationsCount":47},"100572079","protective-effect-of-eecp-against-negative-inflammatory-response-and-organ-dysfunction-after-cardiovascular-surgery-100572079","NCT06728605","Protective Effect of EECP Against Negative Inflammatory Response and Organ Dysfunction After Cardiovascular Surgery","Protective Effect of Enhanced External Counterpulsation Against Negative Inflammatory Response and Organ Dysfunction After Cardiovascular Surgery","PANDA","Inclusion Criteria:\n\n* Age \\> 18 years;\n* Patients with Stable angina pectoris, unstable angina pectoris, acute myocardial infarction, congestive heart failure, cardiogenic shock;\n* Patients chronic heart failure;\n* Patients are ready to received cardiovascular surgery during this hospital admission.\n* Patients agree to participate in the study and sign an informed consent form.\n\nExclusion Criteria:\n\n1\\. Moderate to severe aortic insufficiency; 2. Dissection aneurysm; 3. Significant pulmonary hypertension; 4, A variety of bleeding diseases or bleeding tendencies, or use anticoagulants, INR\\>2.0; 5, active phlebitis, venous thrombosis; 6. There is an infection in the counterpulsating limb; 7. Uncontrolled hyperhypertension (\\>170\u002F110mmHg); 8. Uncontrolled arrhythmias: frequent premature beats, rapid atrial fibrillation, etc.\n\n9\\. Pregnancy.","80 Years",{"count":203,"type":20},400,[23],"Enhanced external counterpulsation (EECP) is a noninvasive, non-pharmacologic intervention proven to increase nitric oxide bioavailability in patients with coronary artery disease. Although EECP showed short-term effects in improving coronary flow in patients with coronary slow flow, whether such improvement is durable remains uncertain, and the relationships between such improvement and changes in multiple organ functions as well as inflammatory markers have not been elucidated. The purpose of this study will be to evaluate the potential clinical benefits of EECP on organ function and proinflammatory cytokine concentrations during post-acute sequela of cardiovascular surgery.",[207,208,29,209],"Coronary Heart Disease (CHD)","Cardio-pulmonary Bypass","Cardiogenic Shock Acute",[211,212,213],"cardiac surgery","cardiopulmonary bypass","cardiogenic shock","2024-12-10",{"date":216,"type":39},"2024-12-11",{"date":218,"type":20},"2025-12-31",{"date":218,"type":20},{"name":221,"class":46},"Nanjing Medical University"]